ADCs Reshaping Endometrial Cancer Care

Expert faculty examine how antibody drug conjugates are changing the treatment landscape in endometrial cancer as more patients receive chemotherapy and immunotherapy earlier in care. The discussion centers on the growing need for effective therapies after progression and on why targets such as HER2, folate receptor alpha, TROPE2, B7H4, and CDH6 are drawing interest in recurrent disease. Attention is given to the practical questions clinicians face as these agents move closer to routine use, including how to interpret early phase data, how to think about payload differences, and how to integrate newer options with established treatment approaches. The conversation also highlights the importance of matching enthusiasm with realism, because promising response data must still translate into durable benefit and manageable toxicity. Overall, the faculty outline a rapidly evolving therapeutic space in which antibody drug conjugates may expand options for patients with difficult to treat disease while also introducing more complexity into everyday clinical decision making.